Earnings summaries and quarterly performance for Tango Therapeutics.
Executive leadership at Tango Therapeutics.
Board of directors at Tango Therapeutics.
Research analysts covering Tango Therapeutics.
Recent press releases and 8-K filings for TNGX.
Tango Therapeutics Announces CEO Transition and New Appointment
TNGX
CEO Change
Management Change
Executive Compensation
- Dr. Barbara Weber retired as CEO of Tango Therapeutics, Inc. on January 8, 2026, and will transition to Executive Chair for 2026.
- Dr. Malte Peters was appointed President and Chief Executive Officer, effective January 8, 2026, with an annual base salary of $720,000 and a target cash bonus opportunity of 60% of his base salary. He was also granted an option to purchase 1,650,000 shares and 350,000 restricted stock units.
- As of December 31, 2025, the company reported $343 million in cash, cash equivalents, and marketable securities.
- Tango Therapeutics renewed its guidance for 2026 clinical milestones, including initial safety and efficacy data for combination trials and the start of a pivotal study for vopimetostat monotherapy in 2L pancreatic cancer.
1 day ago
Tango Therapeutics Announces CEO Transition
TNGX
CEO Change
Management Change
Guidance Update
- Tango Therapeutics (NASDAQ: TNGX) announced a leadership transition, with founding CEO Dr. Barbara Weber retiring, effective January 8, 2026.
- Dr. Weber will transition to Executive Chair for 2026 and then serve as non-executive chair starting in 2027.
- Dr. Malte Peters, a current board member, has been appointed President and Chief Executive Officer, effective immediately.
- The company also renewed its guidance on anticipated clinical milestones for 2026, which include initial safety and efficacy data for combination trials and TNG456 monotherapy, a lung cancer update for vopimetostat monotherapy, and the start of a pivotal study for vopimetostat monotherapy in 2L pancreatic cancer.
1 day ago
Tango Therapeutics Provides Clinical Program Updates and Strategic Outlook
TNGX
New Projects/Investments
- Tango Therapeutics (TNGX), a precision oncology company, is focused on novel targets with three clinical programs heading into 2026.
- Their lead program, bopametastat, an MTA cooperative PRMT5 inhibitor, demonstrated an overall response rate of 27% and median PFS of 6.4 months across over 150 patients. In second-line pancreatic cancer, it achieved an ORR of 25% and median PFS of 7.2 months, significantly surpassing the standard of care.
- Tango plans to initiate a pivotal Phase 3 study for bopametastat in second-line pancreatic cancer in 2026, following FDA alignment on the approximately 300-patient trial design.
- The company is also developing TNG456, a brain-penetrant PRMT5 inhibitor for glioblastoma, with data expected in 2026.
- Tango Therapeutics' cash runway extends into 2028, sufficient to cover the first pivotal study and ongoing clinical activities.
Dec 3, 2025, 6:30 PM
Tango Therapeutics Details Bopametastat Clinical Progress and Pivotal Study Plans
TNGX
New Projects/Investments
- Tango Therapeutics (TNGX) presented positive clinical data for bopametastat (formerly TNG462), an MTA cooperative PRMT5 inhibitor, including an overall response rate of 27% and a median PFS of 6.4 months across over 150 patients. In second-line pancreatic cancer, bopametastat achieved a 25% overall response rate and a median PFS of 7.2 months, significantly outperforming standard of care chemotherapy.
- The company has received FDA alignment for the design of a pivotal Phase 3 study for bopametastat in second-line pancreatic cancer, which is slated to begin in 2026. This approximately 300-patient trial will compare bopametastat to standard of care chemotherapy.
- TNGX is also advancing TNG456, a brain-penetrant PRMT5 inhibitor for glioblastoma (GBM), with data anticipated in 2026, and TNG260, which demonstrated early proof of concept in STK11 mutant and KRAS wild type non-small cell lung cancer.
- The company reports a cash runway extending into 2028, sufficient to cover the first pivotal study and all ongoing clinical trial activities.
Dec 3, 2025, 6:30 PM
Tango Therapeutics Updates on Vopimetostat Progress and Extends Cash Runway
TNGX
New Projects/Investments
Guidance Update
- Tango Therapeutics' lead program, vopimetostat, demonstrated an Overall Response Rate (ORR) of 25% and a median Progression-Free Survival (PFS) of 7.2 months in second-line MTAP-deleted pancreatic cancer.
- The company has secured FDA buy-in for the design of its 300-patient pivotal study for second-line pancreatic cancer, which will use a hierarchical design for PFS and OS readouts.
- Combination studies of vopimetostat with RAS inhibitors are enrolling rapidly, with a data update anticipated in 2026; the target ORR for convincing efficacy in pancreatic cancer is 45-50%.
- Tango Therapeutics has extended its cash runway into 2028 following a recent raise of $225 million (net proceeds of $212 million), which is expected to fund current enabling studies and the second-line pivotal study.
Nov 19, 2025, 4:30 PM
Tango Therapeutics Updates on Vopimetostat Clinical Progress and Financial Runway
TNGX
Guidance Update
New Projects/Investments
- Vopimetostat, Tango Therapeutics' lead program, demonstrated a 25% objective response rate (ORR) and a median progression-free survival (PFS) of 7.2 months in second-line pancreatic cancer (PDAC) from its Phase 1/2 study. The company has secured FDA buy-in for the design of a pivotal study for vopimetostat in second-line PDAC, which is expected to enroll approximately 300 patients.
- Combination studies of vopimetostat with RAS inhibitors (daraxonrasib and zoldonrasib) are enrolling quickly, with a data update anticipated in 2026. The target for these combinations is an ORR of 45-50% in pancreatic cancer to potentially enable a first-line study, which could commence in late 2026 or into 2027.
- Tango Therapeutics reported an audited cash position of $153 million and recently raised $225 million (net proceeds of $212 million), extending its cash runway into 2028. This runway supports enabling studies and the second-line pivotal study but does not include additional pivotal studies.
Nov 19, 2025, 4:30 PM
TNGX: Tango Therapeutics Provides Vopimetostat Clinical Updates and Extends Cash Runway
TNGX
New Projects/Investments
Guidance Update
- Tango Therapeutics' lead program, vopimetostat, demonstrated an Overall Response Rate (ORR) of 27% across various difficult-to-treat cancers, including a 25% ORR and median PFS of 7.2 months in second-line pancreatic cancer, which compares favorably to current standard of care. The company has received FDA agreement on the design for a planned 300-patient Phase 3 pivotal study for second-line PDAC.
- Combination studies of vopimetostat with RAS inhibitors (daraxonrasib and zoldonrasib) are enrolling quickly and have been very well tolerated. A data update is expected in 2026, with a target ORR of 45-50% in pancreatic cancer for convincing efficacy, aiming to enable a first-line study.
- The company's next-gen PRMT5 inhibitor, TNGX-456, is in Phase 1 for glioblastoma, with data expected in 2026.
- Tango Therapeutics reported $153 million in audited numbers and recently raised $225 million (net proceeds of $212 million), extending its cash runway into 2028. This runway covers enabling studies and the second-line pivotal study, but not additional pivotal studies.
Nov 19, 2025, 4:30 PM
Tango Therapeutics Reports Q3 2025 Financial Results and Business Highlights
TNGX
Earnings
New Projects/Investments
Guidance Update
- Tango Therapeutics reported a net income of $15.9 million, or $0.14 per share (basic), for the third quarter ended September 30, 2025, a significant improvement from a net loss of $29.2 million, or $0.27 per share, in the same period of 2024.
- Collaboration revenue increased to $53.8 million for the three months ended September 30, 2025, compared to $11.6 million for the same period in 2024, primarily due to the recognition of deferred revenue from the Gilead collaboration.
- As of September 30, 2025, the company held $152.8 million in cash, cash equivalents, and marketable securities, and a $225 million gross proceeds financing in October 2025 is expected to extend its cash runway into 2028.
- Clinical data for vopimetostat (TNG462) showed a median progression-free survival (mPFS) of 7.2 months in 2L MTAP-del pancreatic cancer and a 49% overall response rate (ORR) with mPFS of 9.1 months in a histology-selective cohort of other late-line cancers, supporting a planned pivotal trial in 2026.
- In October 2025, the FDA granted Orphan Drug Designation (ODD) to TNG456 for the treatment of malignant glioma.
Nov 4, 2025, 2:10 PM
Tango Therapeutics Reports Q3 2025 Financial Results and Provides Business Highlights
TNGX
Earnings
Guidance Update
New Projects/Investments
- Tango Therapeutics reported a net income of $15.9 million for the third quarter ended September 30, 2025, or $0.14 per share, compared to a net loss of $29.2 million, or $0.27 per share, for the same period in 2024. Collaboration revenue for Q3 2025 was $53.8 million, up from $11.6 million in Q3 2024.
- As of September 30, 2025, the company held $152.8 million in cash, cash equivalents, and marketable securities. A $225 million gross proceeds financing in October 2025 is expected to extend the cash runway into 2028.
- Clinical data for vopimetostat (TNG462) in 2L MTAP-del pancreatic cancer showed a median progression-free survival (mPFS) of 7.2 months, supporting a planned pivotal study start in 2026. Additionally, a histology-selective cohort demonstrated a 49% objective response rate (ORR) and mPFS of 9.1 months.
- TNG456 was granted Orphan Drug Designation by the FDA for the treatment of malignant glioma in October 2025, with initial safety and efficacy data from its Phase 1/2 trial anticipated in 2026.
Nov 4, 2025, 2:00 PM
Tango Therapeutics, Inc. Announces Equity Offerings to Fund Operations into 2028
TNGX
New Projects/Investments
Guidance Update
- On October 23, 2025, Tango Therapeutics, Inc. entered into an underwriting agreement for a Registered Direct Offering of 21,023,337 shares of common stock and Pre-Funded Warrants to purchase up to 3,226,458 shares of common stock. Each share was offered at $8.66 and each Pre-Funded Warrant at $8.659.
- Concurrently, the company also entered into a securities purchase agreement for a Private Placement of 1,732,101 shares of Common Stock at a purchase price of $8.66 per share.
- The company estimates net proceeds of approximately $197 million from the Registered Direct Offering and gross proceeds of approximately $15 million from the Private Placement.
- The proceeds from both offerings, along with existing cash, are expected to fund the company's operating expenses and capital expenditure requirements into 2028. Both transactions are anticipated to close on October 24, 2025.
Oct 24, 2025, 10:17 AM
Fintool News
In-depth analysis and coverage of Tango Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more